| Posttranslational regulation of Akt in human cancer CH Chan, U Jo, A Kohrman, AH Rezaeian, PC Chou, C Logothetis, ... Cell & bioscience 4, 1-9, 2014 | 153 | 2014 |
| Novel and highly potent ATR inhibitor M4344 kills cancer cells with replication stress and enhances the chemotherapeutic activity of widely used DNA damaging agents U Jo, I Senatorov, A Zimmermann, LK Saha, Y Murai, SH Kim, ... Molecular Cancer Therapeutics (Selected as a highlighted) 20 (8), 1431–1441., 2021 | 89 | 2021 |
| Debulking of topoisomerase DNA-protein crosslinks (TOP-DPC) by the proteasome, non-proteasomal and non-proteolytic pathways Y Sun, LK Saha, S Saha, U Jo, Y Pommier DNA repair 94, 102926, 2020 | 78 | 2020 |
| Allosteric activation of ubiquitin-specific proteases by β-propeller proteins UAF1 and WDR20 H Li, KS Lim, H Kim, TR Hinds, U Jo, H Mao, CE Weller, J Sun, ... Molecular cell 63 (2), 249-260, 2016 | 71 | 2016 |
| Chromatin remodeling and immediate early gene activation by SLFN11 in response to replication stress J Murai, H Zhang, L Pongor, SW Tang, U Jo, F Moribe, Y Ma, M Tomita, ... Cell reports 30 (12), 4137-4151. e6, 2020 | 64 | 2020 |
| EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR U Jo, KH Park, YM Whang, JS Sung, NH Won, JK Park, YH Kim Oncotarget (Selected as cover) 5 (5), 1265, 2014 | 61 | 2014 |
| SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors U Jo, Y Murai, S Chakka, L Chen, K Cheng, J Murai, LK Saha, ... Proceedings of the National Academy of Sciences 118 (6), e2015654118, 2021 | 58 | 2021 |
| Wnt5a is associated with cigarette smoke-related lung carcinogenesis via protein kinase C YM Whang, U Jo, JS Sung, HJ Ju, HK Kim, KH Park, JW Lee, IS Koh, ... PLoS One 8 (1), e53012, 2013 | 48 | 2013 |
| PCNA-dependent cleavage and degradation of SDE2 regulates response to replication stress U Jo, W Cai, J Wang, Y Kwon, AD D’Andrea, H Kim PLoS genetics 12 (12), e1006465, 2016 | 43 | 2016 |
| Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)? ST Kim, JS Sung, UH Jo, KH Park, SW Shin, YH Kim Medical Oncology 30, 1-10, 2013 | 42 | 2013 |
| Structural, molecular, and functional insights into Schlafen proteins U Jo, Y Pommier Experimental & Molecular Medicine 54 (6), 730-738, 2022 | 39 | 2022 |
| The genetic polymorphisms of HER-2 and the risk of lung cancer in a Korean population UH Jo, SGL Han, JH Seo, KH Park, JW Lee, HJ Lee, JS Ryu, YH Kim BMC cancer 8, 1-9, 2008 | 39 | 2008 |
| SLFN11 inactivation induces proteotoxic stress and sensitizes cancer cells to ubiquitin activating enzyme inhibitor TAK-243 Y Murai, U Jo, J Murai, L Jenkins, SYN Huang, S Chakka, L Chen, ... Cancer Research, 2021 | 37 | 2021 |
| DNA and RNA cleavage complexes and repair pathway for TOP3B RNA-and DNA-protein crosslinks S Saha, Y Sun, SN Huang, SA Baechler, LS Pongor, K Agama, U Jo, ... Cell reports 33 (13), 2020 | 37 | 2020 |
| Can serum be used for analyzing the EGFR mutation status in patients with advanced non-small cell lung cancer? ST Kim, HY Jung, JS Sung, UH Jo, T Tanaka, K Hagiwara, KH Park, ... American journal of clinical oncology 36 (1), 57-63, 2013 | 35 | 2013 |
| Precision Oncology with Drugs Targeting the Replication Stress, ATR, and Schlafen 11 U Jo, Y Murai, N Takebe, A Thomas, Y Pommier Cancers 13 (18), 4601, 2021 | 32 | 2021 |
| TOP1-DNA trapping by exatecan and combination therapy with ATR inhibitor U Jo, Y Murai, KK Agama, Y Sun, LK Saha, X Yang, Y Arakawa, S Gayle, ... Molecular cancer therapeutics 21 (7), 1090-1102, 2022 | 30 | 2022 |
| Exploiting the Fanconi anemia pathway for targeted anti-cancer therapy U Jo, H Kim Molecules and cells 38 (8), 669-676, 2015 | 30 | 2015 |
| Replication-dependent cytotoxicity and Spartan-mediated repair of trapped PARP1–DNA complexes LK Saha, Y Murai, S Saha, U Jo, M Tsuda, S Takeda, Y Pommier Nucleic acids research 49 (18), 10493-10506, 2021 | 29 | 2021 |
| Caveolin-1 modulates docetaxel-induced cell death in breast cancer cell subtypes through different mechanisms J Kang, JH Park, HJ Lee, U Jo, JK Park, JH Seo, YH Kim, I Kim, KH Park Cancer research and treatment: official journal of Korean Cancer Association …, 2016 | 28 | 2016 |
Yves PommierChief, Developmental Therapeutics Branch & Laboratory of Molecular PharmacologyVerificeret mail på nih.gov